Report from the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Journal Watch October 5, 2007
“This year, the most important study presented was the ARTEMIS Study, which was an industry-sponsored comparison between ritonavir-boosted darunavir and fixed-dose lopinavir/ritonavir in treatment-naive patients; study participants also received fixed-dose tenofovir/FTC [Abstract H-718b]. …
“These study results are outstanding for both treatment arms and provide a new benchmark for treatment response with PI-based regimens. Furthermore, these findings clearly demonstrate that once-daily ritonavir-boosted darunavir is not inferior to lopinavir/r and, in patients with high baseline viral loads, may well be superior; GI side effects also seem to be less frequent with darunavir than with lopinavir.”
Add comment October 10th, 2007